Pfizer Inc. announced results from two Phase 3 studies of Prevnar 13 (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) for vaccination in adults ≥50 years. Data from both studies showed that Prevnar 13 was at least as immunogenic as the currently licensed nonconjugated pneumococcal polysaccharide vaccine (PPSV) for the 12 serotypes common to both vaccines in the age groups studied who were either pneumococcal vaccine-naïve or previously immunized with PPSV. Furthermore, the secondary endpoint data from both studies showed that Prevnar 13 elicited a statistically significantly higher functional antibody response than PPSV against a majority of serotypes common to both vaccines and serotype 6A, a serotype not contained in PPSV.
Prevnar 13 is a vaccine approved for use in children 6 weeks through 5 years of age. Prevnar 13 is indicated for active immunization for the prevention of invasive disease caused by 13 strains of Streptococcus pneumoniae. Prevnar 13 is also indicated for the prevention of otitis media caused by 7 strains of Streptococcus pneumoniae.
For more information call (212) 733-2323 or visit www.pfizer.com.